X-COR Therapeutics is developing the first commercially available extracorporeal CO2 removal device that utilizes ultra-low blood flow to treat patients with hypercarbic respiratory failure. This device addresses the inadequate current therapies for chronic respiratory conditions by providing a cost-effective and less invasive solution that can be deployed outside of intensive care units.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AHFounders
Product
Problem
Patients with chronic respiratory conditions, such as COPD and cystic fibrosis, or those experiencing acute trauma or respiratory infection, can develop hypercarbic respiratory failure, characterized by elevated CO2 levels in the blood. Current treatments for this condition are often inadequate, leading to millions suffering from breathing difficulties and a diminished quality of life.
Solution
X-COR Therapeutics is developing an extracorporeal CO2 removal device that utilizes ultra-low blood flow to address hypercarbic respiratory failure. The device directly reconditions the blood, allowing the lungs to recover without being overworked. Designed for use outside of intensive care units, the system aims to provide a more accessible and cost-effective solution compared to existing therapies. The technology employs a hybrid cartridge and a machine-learning-based control algorithm to remove CO2 from the patient's blood using less invasive procedures than high-flow alternatives.
Target Audience
The primary target audience includes hospitals, clinicians, and healthcare systems seeking a cost-effective and less invasive solution for treating patients with hypercarbic respiratory failure outside of the intensive care unit.
Features
- Patent-pending medical device for extracorporeal CO2 removal
- Ultra-low blood flow rates (<300 ml/min) via small catheters, minimizing invasiveness
- Hybrid cartridge technology for efficient CO2 removal
- Machine-learning-based control algorithm for precise CO2 regulation
- Compatibility with existing medical device infrastructure for ease of use and rapid deployment
- Designed for use by a broader range of clinicians and hospitals, not limited to specialized ICU staff